New hepatitis b vaccine candidate shows promise in early trial

NCT ID NCT05561673

Completed ⭐️ VACCINE ⭐️ Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new hepatitis B vaccine that includes an experimental booster called AS37. The goal was to see if the vaccine is safe and how well it triggers the immune system. 122 healthy adults aged 18-45 received two doses one month apart. Researchers monitored side effects and measured antibody levels to compare the new vaccine with existing ones.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis B virus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS B

Contacts and locations

Show contact details

Locations

GSK Investigational Site

Leuven, 3000, Belgium
GSK Investigational Site

Cologne, 51069, Germany
GSK Investigational Site

Hamburg, 22143, Germany
GSK Investigational Site

Magdeburg, 39120, Germany
GSK Investigational Site

Cambridge, CB2 2GG, United Kingdom